APC and colorectal cancer: Coherent with the inhibitory activity towards purified TNKS2, treatment of adenomatous polyposis coli (APC)-mutant DLD1 colorectal cancer cells with JNJ-BJ impaired Wnt-driven transcriptional responses, as assessed by both a TOPflash luciferase reporter assay (Fig. 1c; raw data in Additional file 2) and reverse transcription quantitative polymerase chain reaction (RT-qPCR) analysis of the expression of established β-catenin target genes (Fig. 1d; raw data in Additional file 2).